机构:[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.[2]Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.[3]UCD School of Medicine, College of Health and Agricultural Science, Belfield, Dublin, Ireland.[4]UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, UCD, Belfield, Dublin, Ireland.[5]State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China.
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on patient outcome following the use of novel therapies for the past decades, curative treatment is unavailable for the majority of patients. For example, the 5-year survival of MM is currently less than 50%. In the 1980s, interferon-α was used as monotherapy in newly diagnosed or previously treated MM with an overall response rate of 15-20%. Noticeably, a small subset of patients who responded to long-term interferon-α further achieved sustained complete remission. Since 1990, interferon-α-containing regimens have been used as a central maintenance strategy for patients with MM. However, the systemic administration of interferon-α was ultimately limited by its pronounced toxicity. To address this, the selective mAb-mediated delivery of interferon-α has been developed to enhance specific killing of MM and B-cell malignant cells. As such, targeted interferon-α therapy may improve therapeutic window and sustain responses, while further overcoming suppressive microenvironment. This review aims to reinforce the role of interferon-α by consolidating our current understanding of targeting interferon-α with tumor-specific mAbs for B cell lymphoma and myeloma.
基金:
Research Development Fund for Hematological Neoplasm from Chinese Anti-Cancer Association [312160342]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81302148]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1CA050947, RO1CA207237]; DF/HCC SPORE in Multiple Myeloma [P50CA100707]; American Cancer Society Clinical Research ProfessorAmerican Cancer Society
语种:
外文
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
无
最新[2023]版:
大类|1 区医学
小类|2 区血液学2 区肿瘤学
第一作者:
第一作者机构:[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.[2]Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
通讯作者:
通讯机构:[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
推荐引用方式(GB/T 7714):
Li Zhang,Yu-Tzu Tai,Matthew Zhi Guang Ho,et al.Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.[J].Experimental hematology & oncology.2017,6(1):20.doi:10.1186/s40164-017-0081-6.
APA:
Li Zhang,Yu-Tzu Tai,Matthew Zhi Guang Ho,Lugui Qiu&Kenneth C. Anderson.(2017).Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era..Experimental hematology & oncology,6,(1)
MLA:
Li Zhang,et al."Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.".Experimental hematology & oncology 6..1(2017):20